Redeye reviews its assessment of Acarix, acknowledging the clinical and regulatory progress for the CADScor device and the catalysts ahead in the form of acquired reimbursement, high-volume orders, and establishment in the US market. We hike our fair value range as our reassessment suggests a more optimistic take on the case.
LÄS MER